About Unitaid

8 December 2017
Sanne Fournier-Wendes, Senior Advisor to the ED
Agenda

1. Unitaid overview
2. Our portfolio
3. Collaboration with GHIT Fund
Unitaid overview
Growth in development assistance

Development assistance for health ($B)

Source: IHME (Institute for Health Metrics and Evaluation)
Unitaid’s mission relies on 3 strategic objectives

Maximize the effectiveness of the global health response by catalyzing equitable access to better health products

- **Innovation**: Linking pipelines to frontlines
- **Access**: Overcoming market barriers
- **Scalability**: Creating conditions for scale-up
Unitaid plays a role at 3 critical moments

**Objective**

- Innovation
- Access
- Scalability

**Product coverage**

**Moment 1**
Product is available

**Moment 2**
Product is adopted

**Moment 3**
Product is scaled-up

- Maximize the effectiveness of the global health response...
- ...by catalyzing equitable access...
- ...to better health products
Unitaid connects the upstream to the downstream

**Upstream**
- Academia
- Industry
- PDPs
- Gates Foundation
- GHIT Fund
- Others

**Downstream**
- HIV/AIDS
- Tuberculosis
- Malaria
- ...  

**Ensuring access by overcoming market barriers**

- Innovation & Availability
- Quality
- Affordability
- Supply & Delivery
- Demand & Adoption

- Medicines
- Devices
- Systems
Unitaid's Operating Model

- Develop disease narratives
- Identify opportunities for intervention
- Call for proposals
  - Selection of areas for intervention
  - Go-ahead of proposals
- Develop grant
  - Final approval
- Signature & Disbursement
  - Implement & transition / close

Decision gate

Board involvement
Partner engagement is key through entire process

- Anticipate and respond to country needs
- Anticipate upstream innovation
- Ensure readiness to scale-up including funding
Our portfolio
Unitaid’s Core Investment Areas

- HIV
- Tuberculosis
- Malaria
- HIV co-infections, incl. Hepatitis
- Cross-cutting

PREVENT
TEST
TREAT
Unitaid’s Portfolio as at Oct 2017

40 grants

US$ 1 bio.
Children have been under-treated for decades

- ~10% of all TB cases occur among children
- At least 1 million children become ill with TB each year
- TB medicines have been around since 1950s – but no child-friendly version

Unitaid has introduced first child-friendly TB medicine

- 2010: Revised WHO recommendation for TB treatment in children but no manufacturers were responding
- Unitaid & its partners (TB Alliance) have brought child-friendly fixed dose combination to market

Today procured in more than 70 countries
Malaria: Injectable Artesunate - a dramatic reduction in child mortality

Number of vials procured (m)

- 2011: 1.7
- 2015: 10.5 (14x increase)
- 2021: 24.5

Unitaid & partners

Partners

66k children’s lives saved / year

ROI > 100
Collaboration with GHIT Fund
Partner engagement - GHIT

Engagement between GHIT & Unitaid and areas of continued collaboration

• Common **vision & interests**: bring access to new health technologies (e.g. drugs, diagnostics) with potential for game changing impact in developing world

• Participation in **GHIT annual partner meeting** in 2016 and in **R&D Forum** in December 2017

• **Bi-lateral discussions**: 3 meetings in London, New York UNGA 2017 and Geneva Oct 2017

• Mapping in process of potential GHIT investments that could be transitioned to Unitaid, e.g.
  – Common **partners / stakeholders** (Gates Foundation, Otsuka, TB Alliance)
  – Common **priority countries** (e.g. Uganda, Tanzania, Burkina Faso)
  – Common **priority areas** (e.g. Malaria in children, Tuberculosis)
Area of value chain suited to collaboration with GHIT

- **Upstream**
  - Academia
  - Industry
  - PDPs
  - Gates Foundation
  - GHIT Fund
  - Others

  - **Innovation & Availability**
  - **Quality**
  - **Affordability**
  - **Supply & Delivery**
  - **Demand & Adoption**

- **Downstream**
  - HIV/AIDS
  - Tuberculosis
  - Malaria
  - ...
Any questions? Thank you